SEC filing · 8-K

Humacyte, Inc.: Executive or director change

Humacyte appointed Scott Coward and Paul Kuznik to its Board of Directors.

Filed September 28, 2026

Positive for the company

What happened

On September 22, 2026, the Board appointed Scott Coward as a Class I director and Paul Kuznik as a Class II director.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Humacyte, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.